| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |

The Salk Institute La Jolla, California, 92037
The Laboratoire de Psychobiobgie des Comportements Adaptatifs, U259INSERM-INRA 33077 Bordeaux Cedex, France
Address requests for reprints to: Dr. Catherine Rivier, Peptide Biology Laboratory, The Salk Institute, P.O. Box 85800, San Diego, California 92138.
Abstract
Arginine-vasopressin (AVP) acts on vasocon-striction and diuresis through two different types of receptors (V1 and V2, respectively). Since AVP also modifies ACTH release, we have attempted to determine which class of receptors mediates the capacity of AVP to increase ACTH secretion and o t potentiate the effect of corticotropin-releasing factor (CRF) on the pituitary using two AVP antagonists: [1-deaminopenicil-lamine-2-(O-methyl)tyrosine]arginine-vasopressin [dPTyr(Me)-AVP], which blocks Vi receptors, and [1-(β-mercapto-β,β-cyclo-pentamethylene propionic acid)2-D-leucine-4-valine]arginine vasopressin [d(CH2)6DLeuValAVP], which interferes with V2 receptors. dPTyr(Me)AVP, but not d(CH2)6DLeuValAVP, in-hibited the ACTH-releasing as well as the CRF-potentiating effects of both AVP and its antidiuretic analog [1-deamino-8-D-argininejvasopressin (dDAVP). These results suggest that the actions of AVP and dDAVP on the corticotrophs is primarily mediated through V1 (pressor-like) receptors. (Endocrinology 115: 882–886, 1984)
Footnotes
* This work was supported by NIH Grants AM-26741 and HD-13527 and a grant from The Rockefeller Foundation. Research was conducted in part by the Clayton Foundation for Research-California Division.
Investigator, Clayton Foundation.
Received November 17, 1983.
This article has been cited by other articles:
![]() |
F. Spiga, L. R Harrison, S. Wood, D. M Knight, C. P MacSweeney, F. Thomson, M. Craighead, and S. L Lightman Blockade of the V1b receptor reduces ACTH, but not corticosterone secretion induced by stress without affecting basal hypothalamic-pituitary-adrenal axis activity J. Endocrinol., March 1, 2009; 200(3): 273 - 283. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Fujiwara, M. Hiroyama, A. Sanbe, J. Yamauchi, G. Tsujimoto, and A. Tanoue Mutual regulation of vasopressin- and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice J. Endocrinol., February 1, 2007; 192(2): 361 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Carlin, W. W. Vale, and T. L. Bale Vital functions of corticotropin-releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis PNAS, February 28, 2006; 103(9): 3462 - 3467. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Katoh, M Yoshida, Y Kobayashi, M Onodera, K Kogusa, and Y Obara Responses induced by arginine-vasopressin injection in the plasma concentrations of adrenocorticotropic hormone, cortisol, growth hormone and metabolites around weaning time in goats J. Endocrinol., November 1, 2005; 187(2): 249 - 256. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ma, M. J. Shipston, D. Morilak, and J. A. Russell Reduced Hypothalamic Vasopressin Secretion Underlies Attenuated Adrenocorticotropin Stress Responses in Pregnant Rats Endocrinology, March 1, 2005; 146(3): 1626 - 1637. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Houshyar, S. Manalo, and M. F. Dallman Time-Dependent Alterations in mRNA Expression of Brain Neuropeptides Regulating Energy Balance and Hypothalamo-Pituitary-Adrenal Activity after Withdrawal from Intermittent Morphine Treatment J. Neurosci., October 20, 2004; 24(42): 9414 - 9424. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kuwahara, H. Arima, R. Banno, I. Sato, N. Kondo, and Y. Oiso Regulation of Vasopressin Gene Expression by cAMP and Glucocorticoids in Parvocellular Neurons of the Paraventricular Nucleus in Rat Hypothalamic Organotypic Cultures J. Neurosci., November 12, 2003; 23(32): 10231 - 10237. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Fields, S. B. House, and H. Gainer Regulatory Domains in the Intergenic Region of the Oxytocin and Vasopressin Genes that Control their Hypothalamus-Specific Expression In Vitro J. Neurosci., August 27, 2003; 23(21): 7801 - 7809. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Bale, K. R. Anderson, A. J. Roberts, K.-F. Lee, T. R. Nagy, and W. W. Vale Corticotropin-Releasing Factor Receptor-2-Deficient Mice Display Abnormal Homeostatic Responses to Challenges of Increased Dietary Fat and Cold Endocrinology, June 1, 2003; 144(6): 2580 - 2587. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Bale, R. Picetti, A. Contarino, G. F. Koob, W. W. Vale, and K.-F. Lee Mice Deficient for Both Corticotropin-Releasing Factor Receptor 1 (CRFR1) and CRFR2 Have an Impaired Stress Response and Display Sexually Dichotomous Anxiety-Like Behavior J. Neurosci., January 1, 2002; 22(1): 193 - 199. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. Laszlo, C. Varga, I. Pavo, J. Gardi, M. Vecsernyes, M. Galfi, E. Morschl, F. Laszlo, and G. B. Makara Vasopressin pressor receptor-mediated activation of HPA axis by acute ethanol stress in rats Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2001; 280(2): R458 - R465. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Muller, R. Landgraf, J. Preil, I. Sillaber, A. E. Kresse, M. E. Keck, S. Zimmermann, F. Holsboer, and W. Wurst Selective Activation of the Hypothalamic Vasopressinergic System in Mice Deficient for the Corticotropin-Releasing Hormone Receptor 1 Is Dependent on Glucocorticoids Endocrinology, November 1, 2000; 141(11): 4262 - 4269. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Dallman Editorial: Moments in Time--The Neonatal Rat Hypothalamo-Pituitary-Adrenal Axis Endocrinology, May 1, 2000; 141(5): 1590 - 1592. [Full Text] [PDF] |
||||
![]() |
G. W. Dent, M. A. Smith, and S. Levine Rapid Induction of Corticotropin-Releasing Hormone Gene Transcription in the Paraventricular Nucleus of the Developing Rat Endocrinology, May 1, 2000; 141(5): 1593 - 1598. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ferin Stress and the Reproductive Cycle J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1768 - 1774. [Full Text] |
||||
![]() |
S. J. McClennen, D. N. Cortright, and A. F. Seasholtz Regulation of Pituitary Corticotropin-Releasing Hormone-Binding Protein Messenger Ribonucleic Acid Levels by Restraint Stress and Adrenalectomy Endocrinology, November 1, 1998; 139(11): 4435 - 4441. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rabadan-Diehl and G. Aguilera Glucocorticoids Increase Vasopressin V1b Receptor Coupling to Phospholipase C Endocrinology, July 1, 1998; 139(7): 3220 - 3226. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rabadan-Diehl, G. Makara, A. Kiss, S. Lolait, D. Zelena, T. Ochedalski, and G. Aguilera Regulation of Pituitary V1b Vasopressin Receptor Messenger Ribonucleic Acid by Adrenalectomy and Glucocorticoid Administration Endocrinology, December 1, 1997; 138(12): 5189 - 5194. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-M. Ma, A. Levy, and S. L. Lightman Emergence of an Isolated Arginine Vasopressin (AVP) Response to Stress after Repeated Restraint: A Study of Both AVP and Corticotropin-Releasing Hormone Messenger Ribonucleic Acid (RNA) and Heteronuclear RNA Endocrinology, October 1, 1997; 138(10): 4351 - 4357. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Newell-Price, L. Perry, S. Medbak, J. Monson, M. Savage, M. Besser, and A. Grossman A Combined Test Using Desmopressin and Corticotropin-Releasing Hormone in the Differential Diagnosis of Cushing's Syndrome J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 176 - 181. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. RICHARDSON and A. G. ROBINSON Drugs Five Years Later: Desmopressin Ann Intern Med, August 1, 1985; 103(2): 228 - 239. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |